Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Immunomedics to Present at Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 12:26 pm UTC| Business
MORRIS PLAINS, N.J., June 01, 2017 -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today announced that Michael R. Garone, Vice President, Finance and Chief Financial Officer, will present at...